Overview

Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

Status:
Completed
Trial end date:
2018-10-22
Target enrollment:
Participant gender:
Summary
This study seeks to show whether there is a benefit of prescribing Enstilar with Otezla in the treatment of patients with moderate plaque type psoriasis. Subjects will be randomized to study treatment at a 1:1 ratio of Otezla plus Enstilar foam versus Otezla plus vehicle foam.
Phase:
Phase 4
Details
Lead Sponsor:
L.H. Kircik, M.D.
Leon Kircik, M.D.
Treatments:
Apremilast
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Calcipotriene
Calcitriol
Thalidomide